restricted access Index
In lieu of an abstract, here is a brief excerpt of the content:

Index Note: Page numbers in italics indicate figures; ­ those with a t indicate ­ tables or boxes. abciximab, 168–169 acai berry, 348, 355t, 387, 388t acanthosis migrans, 166 accountability, 29; patient’s view of, 32; risk management and, 25 accreditation of health care organ­ izations, 18 acebutlol, 313t acetylcysteine, 297t aconite, 348, 355t, 387, 388t acquired long QT syndrome (aLQTS), 63–72; drugs associated with, 66t, 67t; management of, 69–70, 69t; mechanisms of, 64–66, 65; risk ­ factors for, 67–69, 68t. See also long QT syndrome Action in Diabetes and Vascular Disease (ADVANCE) trial, 195, 200 action potential (AP), 63–66, 64, 65; antiarrhythmics’ effect on, 67t Action to Control Cardiovascular Risk in Diabetes (ACCORD) study group, 195, 200 activities of daily living (ADL), 207t acu­punc­ture, 31 Acute Care for Elders (ACE) model, 210 acute coronary syndrome (ACS): antiplatelet therapy­ after, 168, 169; diagnosis of, 226; lixisenatide and, 197; troponin assay for, 83 addiction, 31, 53 Adenoscan Multicenter Trial Registry, 222 adenosine, 222; arrhythmias from, 55; bradyarrhythmia from, 55; for fractional flow reserve, 229; stress testing with, 222, 227, 245–246; ventricular tachycardia from, 55 adrenal cortical hormone, 58 adrenaline, 58, 195 adrenergic agonists, 41 adrenergic crisis, 190 adrenocorticotropic hormone, 41 adriamycin, 56 adverse drug reactions (ADRs), 8, 9, 48–50; adverse effects versus, 48–49; from antihypertensives , 116–139, 118–119t, 152; categories of, 49; cost of, 116–117; definition of, 49; among el­ derly, 208–209; of estrogen diethylstilbestrol, 10; incidence of, 49–50, 370–371; patient’s perspective of, 30–32; side effects versus, 50; of thalidomide, 10 adverse effects (AEs), 47–49; adverse drug reactions versus, 48–49; definitions of, 6, 49 adverse events, 59, 205; from antihypertensives, 116–139, 118–119t, 152; from dietary supplements, 341; risk management of, 22–26 African Americans: heart failure treatment for, 84; hypernatremia and, 347; hypertension among, 96–97; sudden cardiac death in, 318 Agency for Healthcare Research and Quality (AHRQ), 17–18 air embolism, 249, 250, 265 ajmaline, 67t, 71 ALARA (“as low as reasonably achievable”) princi­ ple, 246, 247 albiglutide, 196t albuterol, 110, 297t alcohol, 53, 313t; arrhythmias from, 55; cirrhosis and, 104t, 120, 122, 125; electrolyte imbalances from, 105; hypertension and, 90t, 95–96; MAO inhibitors and, 375t; nutritional deficiencies from, 39; theophylline and, 294; vitamin A and, 342; withdrawal from, 208 aldosterone antagonists, 59 alfalfa, 348, 355t, 387, 388t alfuzosin, 179–180 aliskiren, 59, 102t, 117–119t, 133–134 allopurinol, 294 aloe vera, 348, 355t, 387–393, 388t alogliptin, 196t, 198 alpha-2 agonists, 102t, 103, 108 alpha-­ blockers, 102t, 103, 108, 179–180; adverse effects of, 117t, 118–119t, 136–138; urinary effects of, 179 alpha-­ receptor agonists, 58 alpha-­ receptor modulators, 59 Alpha-­ Tocopherol, Beta Carotene Cancer Prevention Study (ATBC), 342 alteplase, 60 alternative medicine, 10, 31; dietary supplements and, 93t, 337–358, 355–358t, 370–402, 388–394t; naturopathy and, 34–44 Alzheimer’s disease, 332 amalaki, 348, 355t, 388t, 393 amantadine, 66t ambulatory blood pressure monitoring (ABPM), 89 American College of Lifestyle Medicine, 333 American Diabetes Association (ADA), 194, 197 American Medical Association (AMA), 29, 35 American Society for Healthcare Risk Management (ASHRM), 22 American Society of Echocardiography (ASE), 78t, 82, 224 amiloride, 102t, 103, 104 amiodarone, 52; action potential with, 67t; acute repiratory distress syndrome and, 290; torsade de pointes from, 66t; ventricular arrhythmia from, 55 416 / Index amlodipine, 102t, 107, 136; angioedema from, 135; hypotension from, 59 amoxicillin, 295 amphetamines, 313t, 314; hypertension from, 36, 58, 90t; myo­ car­ dial ischemia from, 59 Amplatzer Cardiac Plug (ACP), 249 amsacrine, 66t, 79t anaerobic power, 322 anaphylaxis, 234, 240t andrographis, 348, 355t, 388t, 393 anemia, 234t; hemolytic, 344; hospital-­ acquired, 208 aneurysm, 244 angina, 188–192; from direct vasodilators, 138; Prinzmetal, 189 angioedema, 129; from antihypertensives, 49, 118t, 129, 131–132; from calcium channel blockers, 135 angiogenesis inhibitors, 94–95, 95t angiotensin-­ converting enzyme (ACE) inhibitors, 102t, 106, 107, 117t; adverse effects of, 118–119t, 128–131; angioedema from, 49, 118t; for chemotherapy-­ induced cardiotoxicity, 84, 85; complications with, 37; COX inhibitors with, 91; hypotension with, 59; nutritional deficiencies from, 37; potassium-­ sparing diuretics and, 110–111; spironolactone with, 106, 126 angiotensin-­ receptor blockers (ARBs), 37, 68, 102t, 103, 106, 108, 117t; adverse effects of, 118–119t, 131–133; bradykinin and, 129; cancer risk with, 133; for chemotherapy-­ induced cardiotoxicity, 84, 85; COX inhibitors with, 91; hypotension with, 59; potassium-­ sparing diuretics and, 110–111, 126 Anglo-­ Scandinavian Cardiac Outcomes Trial (ASCOT), 126, 179 anorexia nervosa, 53...


pdf